| Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.J Am Acad Dermatol | PMID 38296199无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase 3 active-controlled trial of liposomal bupivacaine via sciatic nerve block in the popliteal fossa after bunionectomy.J Clin Anesth | PMID 38340677无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.J Hepatol | PMID 38340811无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial).Clin Lung Cancer | PMID 38360496无 PMCID | 2024-Jun | 0.95 | This is a randomized, Phase III, human oncology trial with a primary time-to-event endpoint (overall survival). However, it is excluded because (1) the intervention is surgical comparison, not a drug-containing intervention, and (2) the abstract describes the trial's initiation and design, not the reporting of formal efficacy results. | 待处理 |
| Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline.Clin Pharmacol Ther | PMID 38369951PMC13035048 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.Eur Urol | PMID 38418343PMC12011061 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.Diabetes Obes Metab | PMID 38425186无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.J Neurol | PMID 38430272PMC11136778 | 2024-Jun | 0.95 | Study is not oncology (tropical spastic paraparesis is a neurodegenerative disease, not a human malignant neoplasm) and lacks a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Visual Outcome and Fluid Changes Between Eyes With Polypoidal Choroidal Vasculopathy Receiving Biosimilar CKD-701 or Reference Ranibizumab Therapy: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.Curr Eye Res | PMID 38450631无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.Lancet Infect Dis | PMID 38460525无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.Nutr Clin Pract | PMID 38491966无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.Br J Haematol | PMID 38494194无 PMCID | 2024-Jun | 0.75 | The record describes a proof-of-concept pharmacokinetic modelling study within the context of phase II/III oncology trials. While it meets the oncology, human, randomized, and definitive phase criteria, the primary outcome reported is pharmacokinetic parameters, not the required survival, progression, or other time-to-event efficacy endpoints. Therefore, it is excluded. | 待处理 |
| A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.CPT Pharmacometrics Syst Pharmacol | PMID 38532270PMC11179695 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.J Pharmacokinet Pharmacodyn | PMID 38551711PMC11136851 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.Radiother Oncol | PMID 38552845无 PMCID | 2024-Jun | 0.95 | Study meets oncology, human, randomized, Phase III, and original report criteria, but the primary outcome is testosterone recovery (a biological/pharmacokinetic endpoint), not a clinical efficacy time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP) with a Kaplan-Meier or HR analysis. | 待处理 |
| A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity-Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma.Clin Oncol (R Coll Radiol) | PMID 38553363无 PMCID | 2024-Jun | 0.85 | The study is a randomized Phase II feasibility trial comparing radiotherapy dose escalation techniques in neuroblastoma. It meets criteria for oncology, human, and randomized trial. However, it is excluded because: 1) the intervention is radiotherapy dose/fractionation, not a drug-containing intervention; 2) it is a Phase II trial, not a definitive Phase III/IIIb or Phase II/III trial; and 3) no time-to-event efficacy endpoint (such as OS, PFS, DFS, EFS, RFS, TTP, or HR) is reported as a primary or key secondary outcome; the results focus on feasibility and dosimetric parameters. | 待处理 |
| Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.Diabetes Obes Metab | PMID 38558508无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.Allergy | PMID 38563683无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reducing Salivary Toxicity with Adaptive Radiotherapy (ReSTART): A Randomized Controlled Trial Comparing Conventional IMRT to Adaptive IMRT in Head and Neck Squamous Cell Carcinomas.Clin Oncol (R Coll Radiol) | PMID 38575432无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.Epilepsia Open | PMID 38576178PMC11145603 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes.Muscle Nerve | PMID 38593477无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.Expert Rev Pharmacoecon Outcomes Res | PMID 38594905无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.J Atten Disord | PMID 38600754PMC11107132 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.J Dermatol | PMID 38619178PMC11483935 | 2024-Jun | 0.90 | The record is a Phase III randomized trial with a drug intervention (sirolimus gel) in an oncology/dermatology context (angiofibromas in tuberous sclerosis), but the reported outcomes are for validation of a scoring system (IFA) and its correlation with a clinical composite endpoint. There is no time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis reported. Therefore, it does not meet the core requirement of a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial.J Urol | PMID 38620056无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.CPT Pharmacometrics Syst Pharmacol | PMID 38622879PMC11179702 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dravet syndrome seizure frequency and clustering: Placebo-treated patients in clinical trials.Epilepsy Behav | PMID 38643658无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| AG-920 (Articaine) Ophthalmic Solution: A Masked, Active-Controlled Evaluation of Its Local Anesthetic Efficacy and Safety in Pediatric Patients.J Ocul Pharmacol Ther | PMID 38647654无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A transdiagnostic group exercise intervention for mental health outpatients in Germany (ImPuls): results of a pragmatic, multisite, block-randomised, phase 3 controlled trial.Lancet Psychiatry | PMID 38670127无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.Leukemia | PMID 38678093PMC11147755 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.Adv Ther | PMID 38691316PMC11133178 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.J Child Adolesc Psychopharmacol | PMID 38700708无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Efficacy and Tolerability of Irbesartan/Amlodipine Combination Therapy in Patients With Essential Hypertension Whose Blood Pressure Were not Controlled by Irbesartan Monotherapy.Clin Ther | PMID 38704294无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial.EBioMedicine | PMID 38718683PMC11096868 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.Eur J Cancer | PMID 38723373无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.Drugs R D | PMID 38727860PMC11315842 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.Lancet HIV | PMID 38734015无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.Lancet HIV | PMID 38734016无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.Lancet Rheumatol | PMID 38734019无 PMCID | 2024-Jun | 0.95 | The trial is a randomized, controlled Phase III study in immunocompromised patients, but it is not an oncology trial (focused on COVID-19 vaccination in a general immunocompromised population, not specifically cancer). It does not have a time-to-event efficacy endpoint; the primary outcome is immunogenicity (antibody titers and T-cell responses). The interventions are vaccines, not drug therapies for cancer. Therefore, it does not meet the eligibility criteria for an oncology Kaplan-Meier digitization cohort. | 待处理 |
| Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial.Lancet Respir Med | PMID 38740044PMC11136673 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.Nat Med | PMID 38750351无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| SafeHeal Colovac Colorectal Anastomosis Protection Device evaluation (SAFE-2) pivotal study: an international randomized controlled study to evaluate the safety and effectiveness of the Colovac Colorectal Anastomosis Protection Device.Colorectal Dis | PMID 38750621无 PMCID | 2024-Jun | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.Lancet Neurol | PMID 38760098无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.Lancet Haematol | PMID 38796193无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.NEJM Evid | PMID 38804790无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 38821083无 PMCID | 2024-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.Gynecol Oncol | PMID 38834399PMC12903923 | 2024-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.ESMO Open | PMID 38838498PMC11190462 | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Randomized Control Trial of Dexketoprofen/Vitamin B (Thiamine, Pyridoxine and Cyanocobalamin) Fixed-Dose Combination in Post-Traumatic Grade I-II Cervical Sprains.Clin Drug Investig | PMID 38842764PMC11196333 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: A Pooled Analysis of Data from Two Phase 3 Randomized Clinical Trials.Drugs R D | PMID 38874739PMC11315862 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |